Femoropopliteal Disease: Incidence of Restenosis After Endovascular Revascularization and Review of Cost-Effectiveness Analyses

This report focuses on endovascular treatment of femoropopliteal disease. Restenosis is defined as CD-TLR. Incidence of restenosis is reviewed by device (PTA, BMS, DES and DCB) for clinical trials and registries. Restenosis is also assessed in real-world patients, long lesions and by disease severity (CLI versus IC).

Cost-effectiveness studies in the U.S., Germany and the UK are reviewed and analyzed. As with the other PAD literature, cost discussions and cost-effectiveness analyses are sparse.

Price: $5,900

To Purchase:
Call 404-520-6652 or
Contact: yost@thesagegroup.us